---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-029639"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T19:06:06.664161+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Onconetix signs LOI for business combination with Ocuvex; Ocuvex holders to own ~90%

## Summary
- Non-binding LOI with Ocuvex Therapeutics, a private ophthalmic biopharma company with FDA-approved product and late-stage clinical assets.
- Upon closing, Onconetix will issue new shares to acquire all Ocuvex equity; Ocuvex holders to own ~90% of combined company.
- Transaction subject to due diligence, definitive agreement, financing, regulatory and stockholder approvals; no assurance of completion.
- Onconetix Chairman Andrew J. Oakley states combination will 'immediately expand our reach beyond oncology, enhancing shareholder value.'
- Ocuvex President/CEO Anthony W. Amato notes combining will 'broaden access to capital.'

## SEC filing metadata
- accession: 0001213900-25-029639
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/0001213900-25-029639-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/ea0237471-8k_oncon.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-029639
- JSON: https://secwatch.observer/filing/0001213900-25-029639.json
- Plain text: https://secwatch.observer/filing/0001213900-25-029639.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.